Lineage Cell Therapeutics, Inc.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. carries a market capitalization of 295.40M, placing it among publicly traded companies globally. Its enterprise value stands at 251.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lineage Cell Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. has 252.91M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 24.64, and the price-to-book ratio stands at 5.54.

These figures are as of June 30, 2026. The EV/Sales ratio of 22.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 251.94M versus a market cap of 295.40M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. maintains a current ratio of 6.61, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Lineage Cell Therapeutics, Inc. posted a negative return on equity (ROE) of -59.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.75, reflecting losses generated across the asset base. The company generates approximately 148,721.43 in revenue per employee across its workforce of 77.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Lineage Cell Therapeutics, Inc.'s stock has declined approximately 36.20% over the past 52 weeks. The 50-day moving average sits at 0.90, while the 200-day moving average is 1.16.

Over the twelve months ended June 30, 2026, Lineage Cell Therapeutics, Inc. generated 11.45M in revenue and converted that into -28.24M in net income, yielding earnings per share of -0.11. EBITDA reached -22.85M, while operating income came in at -23.50M.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. holds 44.49M in cash and equivalents against 2.01M in total debt, resulting in a net debt position of -32.70M. Total book value stands at 53.32M, with working capital of 39.35M providing operational flexibility.

Lineage Cell Therapeutics, Inc. produced -20.85M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -502,422.20 in capital expenditures, free cash flow totaled -21.35M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, Lineage Cell Therapeutics, Inc. posted a gross margin of 99.46, reflecting its pricing power and cost economics. The operating margin of -205.23 and net profit margin of -246.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.55, meaning Lineage Cell Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lineage Cell Therapeutics, Inc.'s most recent stock split took place on October 31, 1997 with a 1:3 split ratio.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. has an Altman Z-Score of -6.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.